Review



ll 2 cells  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    ATCC ll 2 cells
    The loss of SRC-3 in Treg suppress lung cancer progression in mice: (A) Experimental design for the orthotopic injection of lung cancer cells (luciferase labeled <t>LL/2)</t> into lung of mouse, followed by tamoxifen treatment to induce SRC-3 KO Tregs. (B) In vivo imaging analysis of luciferase activity in lung cancer-bearing SRC-3 f/f ( n = 5) and SRC-3 f/f :Foxp3 ERT2Cre/Y ( n = 5) male mice treated with tamoxifen. The lung tumor luciferase signal was very weak before tamoxifen treatment. Therefore, the luciferase image was overexposed to determine whether lung cancer cells had established in the lung. (C) H&E staining of lung from #2 and #5 SRC-3 f/f :Foxp3 ERT2Cre/Y in panel B. (D) Quantification of luciferase activity in lung cancer-bearing SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice from panel B. Each line represents a single mouse. (E) Tumor luciferase activity was measured across three independent experiments. The total number of mice used for the SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y groups was 10 and 10, respectively. Luciferase activity was recorded for each mouse at the conclusion of the experiment. (F) Survival curve of SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice with lung cancer. (G) Representative H&E staining of lung cancers harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice. Arrowheads indicated the lung cancer mass. (H–J) Levels of CD4⁺ T cells (H), CD8⁺ T cells (I), and NK cells, identified by CD49b staining (J), were assessed in melanomas harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice using IHC and quantified with the QuPath software. Statistical significance was determined using an unpaired two-tailed Student’s t -test in GraphPad Prism.
    Ll 2 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1275 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ll 2 cells/product/ATCC
    Average 99 stars, based on 1275 article reviews
    ll 2 cells - by Bioz Stars, 2026-03
    99/100 stars

    Images

    1) Product Images from "Steroid receptor coactivator 3-deficient regulatory T cells eradicate multiple solid tumors in syngeneic mouse models"

    Article Title: Steroid receptor coactivator 3-deficient regulatory T cells eradicate multiple solid tumors in syngeneic mouse models

    Journal: Oncoimmunology

    doi: 10.1080/2162402X.2026.2640261

    The loss of SRC-3 in Treg suppress lung cancer progression in mice: (A) Experimental design for the orthotopic injection of lung cancer cells (luciferase labeled LL/2) into lung of mouse, followed by tamoxifen treatment to induce SRC-3 KO Tregs. (B) In vivo imaging analysis of luciferase activity in lung cancer-bearing SRC-3 f/f ( n = 5) and SRC-3 f/f :Foxp3 ERT2Cre/Y ( n = 5) male mice treated with tamoxifen. The lung tumor luciferase signal was very weak before tamoxifen treatment. Therefore, the luciferase image was overexposed to determine whether lung cancer cells had established in the lung. (C) H&E staining of lung from #2 and #5 SRC-3 f/f :Foxp3 ERT2Cre/Y in panel B. (D) Quantification of luciferase activity in lung cancer-bearing SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice from panel B. Each line represents a single mouse. (E) Tumor luciferase activity was measured across three independent experiments. The total number of mice used for the SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y groups was 10 and 10, respectively. Luciferase activity was recorded for each mouse at the conclusion of the experiment. (F) Survival curve of SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice with lung cancer. (G) Representative H&E staining of lung cancers harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice. Arrowheads indicated the lung cancer mass. (H–J) Levels of CD4⁺ T cells (H), CD8⁺ T cells (I), and NK cells, identified by CD49b staining (J), were assessed in melanomas harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice using IHC and quantified with the QuPath software. Statistical significance was determined using an unpaired two-tailed Student’s t -test in GraphPad Prism.
    Figure Legend Snippet: The loss of SRC-3 in Treg suppress lung cancer progression in mice: (A) Experimental design for the orthotopic injection of lung cancer cells (luciferase labeled LL/2) into lung of mouse, followed by tamoxifen treatment to induce SRC-3 KO Tregs. (B) In vivo imaging analysis of luciferase activity in lung cancer-bearing SRC-3 f/f ( n = 5) and SRC-3 f/f :Foxp3 ERT2Cre/Y ( n = 5) male mice treated with tamoxifen. The lung tumor luciferase signal was very weak before tamoxifen treatment. Therefore, the luciferase image was overexposed to determine whether lung cancer cells had established in the lung. (C) H&E staining of lung from #2 and #5 SRC-3 f/f :Foxp3 ERT2Cre/Y in panel B. (D) Quantification of luciferase activity in lung cancer-bearing SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice from panel B. Each line represents a single mouse. (E) Tumor luciferase activity was measured across three independent experiments. The total number of mice used for the SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y groups was 10 and 10, respectively. Luciferase activity was recorded for each mouse at the conclusion of the experiment. (F) Survival curve of SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice with lung cancer. (G) Representative H&E staining of lung cancers harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice. Arrowheads indicated the lung cancer mass. (H–J) Levels of CD4⁺ T cells (H), CD8⁺ T cells (I), and NK cells, identified by CD49b staining (J), were assessed in melanomas harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice using IHC and quantified with the QuPath software. Statistical significance was determined using an unpaired two-tailed Student’s t -test in GraphPad Prism.

    Techniques Used: Injection, Luciferase, Labeling, In Vivo Imaging, Activity Assay, Staining, Software, Two Tailed Test



    Similar Products

    99
    ATCC ll 2 cells
    The loss of SRC-3 in Treg suppress lung cancer progression in mice: (A) Experimental design for the orthotopic injection of lung cancer cells (luciferase labeled <t>LL/2)</t> into lung of mouse, followed by tamoxifen treatment to induce SRC-3 KO Tregs. (B) In vivo imaging analysis of luciferase activity in lung cancer-bearing SRC-3 f/f ( n = 5) and SRC-3 f/f :Foxp3 ERT2Cre/Y ( n = 5) male mice treated with tamoxifen. The lung tumor luciferase signal was very weak before tamoxifen treatment. Therefore, the luciferase image was overexposed to determine whether lung cancer cells had established in the lung. (C) H&E staining of lung from #2 and #5 SRC-3 f/f :Foxp3 ERT2Cre/Y in panel B. (D) Quantification of luciferase activity in lung cancer-bearing SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice from panel B. Each line represents a single mouse. (E) Tumor luciferase activity was measured across three independent experiments. The total number of mice used for the SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y groups was 10 and 10, respectively. Luciferase activity was recorded for each mouse at the conclusion of the experiment. (F) Survival curve of SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice with lung cancer. (G) Representative H&E staining of lung cancers harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice. Arrowheads indicated the lung cancer mass. (H–J) Levels of CD4⁺ T cells (H), CD8⁺ T cells (I), and NK cells, identified by CD49b staining (J), were assessed in melanomas harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice using IHC and quantified with the QuPath software. Statistical significance was determined using an unpaired two-tailed Student’s t -test in GraphPad Prism.
    Ll 2 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ll 2 cells/product/ATCC
    Average 99 stars, based on 1 article reviews
    ll 2 cells - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    99
    ATCC llc cell line
    The loss of SRC-3 in Treg suppress lung cancer progression in mice: (A) Experimental design for the orthotopic injection of lung cancer cells (luciferase labeled <t>LL/2)</t> into lung of mouse, followed by tamoxifen treatment to induce SRC-3 KO Tregs. (B) In vivo imaging analysis of luciferase activity in lung cancer-bearing SRC-3 f/f ( n = 5) and SRC-3 f/f :Foxp3 ERT2Cre/Y ( n = 5) male mice treated with tamoxifen. The lung tumor luciferase signal was very weak before tamoxifen treatment. Therefore, the luciferase image was overexposed to determine whether lung cancer cells had established in the lung. (C) H&E staining of lung from #2 and #5 SRC-3 f/f :Foxp3 ERT2Cre/Y in panel B. (D) Quantification of luciferase activity in lung cancer-bearing SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice from panel B. Each line represents a single mouse. (E) Tumor luciferase activity was measured across three independent experiments. The total number of mice used for the SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y groups was 10 and 10, respectively. Luciferase activity was recorded for each mouse at the conclusion of the experiment. (F) Survival curve of SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice with lung cancer. (G) Representative H&E staining of lung cancers harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice. Arrowheads indicated the lung cancer mass. (H–J) Levels of CD4⁺ T cells (H), CD8⁺ T cells (I), and NK cells, identified by CD49b staining (J), were assessed in melanomas harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice using IHC and quantified with the QuPath software. Statistical significance was determined using an unpaired two-tailed Student’s t -test in GraphPad Prism.
    Llc Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/llc cell line/product/ATCC
    Average 99 stars, based on 1 article reviews
    llc cell line - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    99
    ATCC murine lewis lung carcinoma llc1 ll 2 cells
    The loss of SRC-3 in Treg suppress lung cancer progression in mice: (A) Experimental design for the orthotopic injection of lung cancer cells (luciferase labeled <t>LL/2)</t> into lung of mouse, followed by tamoxifen treatment to induce SRC-3 KO Tregs. (B) In vivo imaging analysis of luciferase activity in lung cancer-bearing SRC-3 f/f ( n = 5) and SRC-3 f/f :Foxp3 ERT2Cre/Y ( n = 5) male mice treated with tamoxifen. The lung tumor luciferase signal was very weak before tamoxifen treatment. Therefore, the luciferase image was overexposed to determine whether lung cancer cells had established in the lung. (C) H&E staining of lung from #2 and #5 SRC-3 f/f :Foxp3 ERT2Cre/Y in panel B. (D) Quantification of luciferase activity in lung cancer-bearing SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice from panel B. Each line represents a single mouse. (E) Tumor luciferase activity was measured across three independent experiments. The total number of mice used for the SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y groups was 10 and 10, respectively. Luciferase activity was recorded for each mouse at the conclusion of the experiment. (F) Survival curve of SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice with lung cancer. (G) Representative H&E staining of lung cancers harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice. Arrowheads indicated the lung cancer mass. (H–J) Levels of CD4⁺ T cells (H), CD8⁺ T cells (I), and NK cells, identified by CD49b staining (J), were assessed in melanomas harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice using IHC and quantified with the QuPath software. Statistical significance was determined using an unpaired two-tailed Student’s t -test in GraphPad Prism.
    Murine Lewis Lung Carcinoma Llc1 Ll 2 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/murine lewis lung carcinoma llc1 ll 2 cells/product/ATCC
    Average 99 stars, based on 1 article reviews
    murine lewis lung carcinoma llc1 ll 2 cells - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    99
    ATCC murine lewis lung carcinoma llc cell line
    The loss of SRC-3 in Treg suppress lung cancer progression in mice: (A) Experimental design for the orthotopic injection of lung cancer cells (luciferase labeled <t>LL/2)</t> into lung of mouse, followed by tamoxifen treatment to induce SRC-3 KO Tregs. (B) In vivo imaging analysis of luciferase activity in lung cancer-bearing SRC-3 f/f ( n = 5) and SRC-3 f/f :Foxp3 ERT2Cre/Y ( n = 5) male mice treated with tamoxifen. The lung tumor luciferase signal was very weak before tamoxifen treatment. Therefore, the luciferase image was overexposed to determine whether lung cancer cells had established in the lung. (C) H&E staining of lung from #2 and #5 SRC-3 f/f :Foxp3 ERT2Cre/Y in panel B. (D) Quantification of luciferase activity in lung cancer-bearing SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice from panel B. Each line represents a single mouse. (E) Tumor luciferase activity was measured across three independent experiments. The total number of mice used for the SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y groups was 10 and 10, respectively. Luciferase activity was recorded for each mouse at the conclusion of the experiment. (F) Survival curve of SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice with lung cancer. (G) Representative H&E staining of lung cancers harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice. Arrowheads indicated the lung cancer mass. (H–J) Levels of CD4⁺ T cells (H), CD8⁺ T cells (I), and NK cells, identified by CD49b staining (J), were assessed in melanomas harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice using IHC and quantified with the QuPath software. Statistical significance was determined using an unpaired two-tailed Student’s t -test in GraphPad Prism.
    Murine Lewis Lung Carcinoma Llc Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/murine lewis lung carcinoma llc cell line/product/ATCC
    Average 99 stars, based on 1 article reviews
    murine lewis lung carcinoma llc cell line - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    99
    ATCC crl 2539 murine lewis lung carcinoma llc1 ll 2 cells atcc
    The loss of SRC-3 in Treg suppress lung cancer progression in mice: (A) Experimental design for the orthotopic injection of lung cancer cells (luciferase labeled <t>LL/2)</t> into lung of mouse, followed by tamoxifen treatment to induce SRC-3 KO Tregs. (B) In vivo imaging analysis of luciferase activity in lung cancer-bearing SRC-3 f/f ( n = 5) and SRC-3 f/f :Foxp3 ERT2Cre/Y ( n = 5) male mice treated with tamoxifen. The lung tumor luciferase signal was very weak before tamoxifen treatment. Therefore, the luciferase image was overexposed to determine whether lung cancer cells had established in the lung. (C) H&E staining of lung from #2 and #5 SRC-3 f/f :Foxp3 ERT2Cre/Y in panel B. (D) Quantification of luciferase activity in lung cancer-bearing SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice from panel B. Each line represents a single mouse. (E) Tumor luciferase activity was measured across three independent experiments. The total number of mice used for the SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y groups was 10 and 10, respectively. Luciferase activity was recorded for each mouse at the conclusion of the experiment. (F) Survival curve of SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice with lung cancer. (G) Representative H&E staining of lung cancers harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice. Arrowheads indicated the lung cancer mass. (H–J) Levels of CD4⁺ T cells (H), CD8⁺ T cells (I), and NK cells, identified by CD49b staining (J), were assessed in melanomas harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice using IHC and quantified with the QuPath software. Statistical significance was determined using an unpaired two-tailed Student’s t -test in GraphPad Prism.
    Crl 2539 Murine Lewis Lung Carcinoma Llc1 Ll 2 Cells Atcc, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/crl 2539 murine lewis lung carcinoma llc1 ll 2 cells atcc/product/ATCC
    Average 99 stars, based on 1 article reviews
    crl 2539 murine lewis lung carcinoma llc1 ll 2 cells atcc - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    99
    ATCC lewis lung carcinoma cells
    The loss of SRC-3 in Treg suppress lung cancer progression in mice: (A) Experimental design for the orthotopic injection of lung cancer cells (luciferase labeled <t>LL/2)</t> into lung of mouse, followed by tamoxifen treatment to induce SRC-3 KO Tregs. (B) In vivo imaging analysis of luciferase activity in lung cancer-bearing SRC-3 f/f ( n = 5) and SRC-3 f/f :Foxp3 ERT2Cre/Y ( n = 5) male mice treated with tamoxifen. The lung tumor luciferase signal was very weak before tamoxifen treatment. Therefore, the luciferase image was overexposed to determine whether lung cancer cells had established in the lung. (C) H&E staining of lung from #2 and #5 SRC-3 f/f :Foxp3 ERT2Cre/Y in panel B. (D) Quantification of luciferase activity in lung cancer-bearing SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice from panel B. Each line represents a single mouse. (E) Tumor luciferase activity was measured across three independent experiments. The total number of mice used for the SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y groups was 10 and 10, respectively. Luciferase activity was recorded for each mouse at the conclusion of the experiment. (F) Survival curve of SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice with lung cancer. (G) Representative H&E staining of lung cancers harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice. Arrowheads indicated the lung cancer mass. (H–J) Levels of CD4⁺ T cells (H), CD8⁺ T cells (I), and NK cells, identified by CD49b staining (J), were assessed in melanomas harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice using IHC and quantified with the QuPath software. Statistical significance was determined using an unpaired two-tailed Student’s t -test in GraphPad Prism.
    Lewis Lung Carcinoma Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lewis lung carcinoma cells/product/ATCC
    Average 99 stars, based on 1 article reviews
    lewis lung carcinoma cells - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    99
    ATCC cell culture 3ll
    The loss of SRC-3 in Treg suppress lung cancer progression in mice: (A) Experimental design for the orthotopic injection of lung cancer cells (luciferase labeled <t>LL/2)</t> into lung of mouse, followed by tamoxifen treatment to induce SRC-3 KO Tregs. (B) In vivo imaging analysis of luciferase activity in lung cancer-bearing SRC-3 f/f ( n = 5) and SRC-3 f/f :Foxp3 ERT2Cre/Y ( n = 5) male mice treated with tamoxifen. The lung tumor luciferase signal was very weak before tamoxifen treatment. Therefore, the luciferase image was overexposed to determine whether lung cancer cells had established in the lung. (C) H&E staining of lung from #2 and #5 SRC-3 f/f :Foxp3 ERT2Cre/Y in panel B. (D) Quantification of luciferase activity in lung cancer-bearing SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice from panel B. Each line represents a single mouse. (E) Tumor luciferase activity was measured across three independent experiments. The total number of mice used for the SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y groups was 10 and 10, respectively. Luciferase activity was recorded for each mouse at the conclusion of the experiment. (F) Survival curve of SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice with lung cancer. (G) Representative H&E staining of lung cancers harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice. Arrowheads indicated the lung cancer mass. (H–J) Levels of CD4⁺ T cells (H), CD8⁺ T cells (I), and NK cells, identified by CD49b staining (J), were assessed in melanomas harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice using IHC and quantified with the QuPath software. Statistical significance was determined using an unpaired two-tailed Student’s t -test in GraphPad Prism.
    Cell Culture 3ll, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cell culture 3ll/product/ATCC
    Average 99 stars, based on 1 article reviews
    cell culture 3ll - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    99
    ATCC lewis lung carcinoma cell line ll 2 llc1
    The loss of SRC-3 in Treg suppress lung cancer progression in mice: (A) Experimental design for the orthotopic injection of lung cancer cells (luciferase labeled <t>LL/2)</t> into lung of mouse, followed by tamoxifen treatment to induce SRC-3 KO Tregs. (B) In vivo imaging analysis of luciferase activity in lung cancer-bearing SRC-3 f/f ( n = 5) and SRC-3 f/f :Foxp3 ERT2Cre/Y ( n = 5) male mice treated with tamoxifen. The lung tumor luciferase signal was very weak before tamoxifen treatment. Therefore, the luciferase image was overexposed to determine whether lung cancer cells had established in the lung. (C) H&E staining of lung from #2 and #5 SRC-3 f/f :Foxp3 ERT2Cre/Y in panel B. (D) Quantification of luciferase activity in lung cancer-bearing SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice from panel B. Each line represents a single mouse. (E) Tumor luciferase activity was measured across three independent experiments. The total number of mice used for the SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y groups was 10 and 10, respectively. Luciferase activity was recorded for each mouse at the conclusion of the experiment. (F) Survival curve of SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice with lung cancer. (G) Representative H&E staining of lung cancers harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice. Arrowheads indicated the lung cancer mass. (H–J) Levels of CD4⁺ T cells (H), CD8⁺ T cells (I), and NK cells, identified by CD49b staining (J), were assessed in melanomas harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice using IHC and quantified with the QuPath software. Statistical significance was determined using an unpaired two-tailed Student’s t -test in GraphPad Prism.
    Lewis Lung Carcinoma Cell Line Ll 2 Llc1, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lewis lung carcinoma cell line ll 2 llc1/product/ATCC
    Average 99 stars, based on 1 article reviews
    lewis lung carcinoma cell line ll 2 llc1 - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    Image Search Results


    The loss of SRC-3 in Treg suppress lung cancer progression in mice: (A) Experimental design for the orthotopic injection of lung cancer cells (luciferase labeled LL/2) into lung of mouse, followed by tamoxifen treatment to induce SRC-3 KO Tregs. (B) In vivo imaging analysis of luciferase activity in lung cancer-bearing SRC-3 f/f ( n = 5) and SRC-3 f/f :Foxp3 ERT2Cre/Y ( n = 5) male mice treated with tamoxifen. The lung tumor luciferase signal was very weak before tamoxifen treatment. Therefore, the luciferase image was overexposed to determine whether lung cancer cells had established in the lung. (C) H&E staining of lung from #2 and #5 SRC-3 f/f :Foxp3 ERT2Cre/Y in panel B. (D) Quantification of luciferase activity in lung cancer-bearing SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice from panel B. Each line represents a single mouse. (E) Tumor luciferase activity was measured across three independent experiments. The total number of mice used for the SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y groups was 10 and 10, respectively. Luciferase activity was recorded for each mouse at the conclusion of the experiment. (F) Survival curve of SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice with lung cancer. (G) Representative H&E staining of lung cancers harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice. Arrowheads indicated the lung cancer mass. (H–J) Levels of CD4⁺ T cells (H), CD8⁺ T cells (I), and NK cells, identified by CD49b staining (J), were assessed in melanomas harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice using IHC and quantified with the QuPath software. Statistical significance was determined using an unpaired two-tailed Student’s t -test in GraphPad Prism.

    Journal: Oncoimmunology

    Article Title: Steroid receptor coactivator 3-deficient regulatory T cells eradicate multiple solid tumors in syngeneic mouse models

    doi: 10.1080/2162402X.2026.2640261

    Figure Lengend Snippet: The loss of SRC-3 in Treg suppress lung cancer progression in mice: (A) Experimental design for the orthotopic injection of lung cancer cells (luciferase labeled LL/2) into lung of mouse, followed by tamoxifen treatment to induce SRC-3 KO Tregs. (B) In vivo imaging analysis of luciferase activity in lung cancer-bearing SRC-3 f/f ( n = 5) and SRC-3 f/f :Foxp3 ERT2Cre/Y ( n = 5) male mice treated with tamoxifen. The lung tumor luciferase signal was very weak before tamoxifen treatment. Therefore, the luciferase image was overexposed to determine whether lung cancer cells had established in the lung. (C) H&E staining of lung from #2 and #5 SRC-3 f/f :Foxp3 ERT2Cre/Y in panel B. (D) Quantification of luciferase activity in lung cancer-bearing SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice from panel B. Each line represents a single mouse. (E) Tumor luciferase activity was measured across three independent experiments. The total number of mice used for the SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y groups was 10 and 10, respectively. Luciferase activity was recorded for each mouse at the conclusion of the experiment. (F) Survival curve of SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y male mice with lung cancer. (G) Representative H&E staining of lung cancers harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice. Arrowheads indicated the lung cancer mass. (H–J) Levels of CD4⁺ T cells (H), CD8⁺ T cells (I), and NK cells, identified by CD49b staining (J), were assessed in melanomas harvested 18 d after tamoxifen treatment in SRC-3 f/f and SRC-3 f/f :Foxp3 ERT2Cre/Y mice using IHC and quantified with the QuPath software. Statistical significance was determined using an unpaired two-tailed Student’s t -test in GraphPad Prism.

    Article Snippet: CT-2A (MilliporeSigma, Catalog number: SCC194), B16F10 (American Type Culture Collection, Catalog number: CRL-6475), and LL/2 cells (American Type Culture Collection, Catalog number: CRL-1642) were used to generate syngeneic mouse models of glioblastoma, melanoma, and lung cancer, respectively.

    Techniques: Injection, Luciferase, Labeling, In Vivo Imaging, Activity Assay, Staining, Software, Two Tailed Test